IP Library Granted Patent US 11,028,096
Granted Patent B2
US 11,028,096 · App. 16/348,558 · Granted Jun 8, 2021

Tricyclic P2-ligand containing potent HIV-protease inhibitors against HIV/AIDS

Inventors: Arun K. Ghosh (West Lafayette, IN); Hiroaki Mitsuya (Kumamoto, JP); Prasanth Reddy Nyalapatla (West Lafayette, IN)
Assignee: Purdue Research Foundation
C07D493/06C07D311/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,028,096
App. No.
16/348,558
Granted
Jun 8, 2021
Kind
B2
Abstract

Various embodiments relate to a compound of the formula (I) and (II), wherein X, X 1 , X 2 , X 3 , and R 1 -R 4 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

Claims (34)

1. A compound of the formula (I)

or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein: n is an integer from 0 to 3; X is (—CHR 5 —) m or —O—, wherein m is 1 or 2 and each R 5 is, independently H, alkyl or alkoxy;

X 1 , X 2 , and X 3 are each, independently, (—CHR 5 —) m ;

R 1 is alkyl, alkoxy, aryl, heterocycyl, halo, hydroxy or amino;

R 2 is alkyl;

R 3 is aryl, benzthiazole, benzoxazole, benzofuranyl or indolyl; and

R 4 is H, alkyl or alkoxy.

2. The compound of claim 1 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein:

X 1 is (—CHR 5 —) m , wherein m is 2;

X 2 is (—CHR 5 —) m , wherein m is 1;

X 3 is (—CHR 5 —) m , wherein m is 1; and

wherein each R 5 is independently H, alkyl or alkoxy.

3. The compound of claim 1 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein:

X 1 is (—CHR 5 —) m , wherein m is 1;

X 2 is (—CHR 5 —) m , wherein m is 1;

X 3 is (—CHR 5 —) m , wherein m is 2; and

wherein each R 5 is independently H, alkyl or alkoxy.

4. The compound of claim 1 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein X is O.

5. The compound of claim 1 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein X is (—CHR 5 —) m , wherein m is 1 and R 5 is H, alkyl or alkoxy.

6. The compound of claim 1 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein R 4 can be H or alkoxy.

7. The compound of claim 1 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein the compound of the formula (I) is a compound of the formula:

or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein n, R 1 , R 2 , R 3 , and R 4 are as defined in claim 1 .

8. The compound of claim 1 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein n is 0.

9. The compound of claim 1 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein R 2 is unsubstituted alkyl.

10. The compound of claim 1 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein R 3 is aryl, benzthiazole or benzoxazole.

11. The compound of claim 10 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein R 3 is phenyl.

12. The compound of claim 10 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein R 3 is:

13. The compound of claim 12 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein R 3 is:

14. The compound of claim 10 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein R 3 is:

wherein R 6 is alkyl, alkylamino, cycloalkylamino, cycloalkyl heterocycloamino, heterocyclo cycloalkylamino or heterocycloamino; and

X 4 is S, O or NR 7 , wherein R 7 is H, alklyl, cycloalkyl or alkylaryl.

15. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, polymorph, or solvate thereof.

16. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, polymorph, or solvate thereof, and one or more pharmaceutically acceptable excipients.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2020
From: GHOSH, ARUN K; MITSUYA, HIROAKI; NYALAPATLA, PRASANTH REDDY
To: PURDUE RESEARCH FOUNDATION
Reel/Frame 053769/0713 →
Continuity (2)
Provisional Application 62419850 · Nov 9, 2016
Related Publication 20190359626A1 · Nov 28, 2019